FDA: Tell patients about risks of ADHD drugs

The Food and Drug Administration on Wednesday announced its decision to require manufacturers of medications approved to treat Attention Deficit Hyperactivity Disorder (ADHD) to inform patients of possible adverse effects of using all types of ADHD drugs and approaches that can be used to minimize the risks. The drugs of concern include Adderall, Adderall XR, Concerta, Daytrana, Desoxyn, Dexedrine, Focalin, Focalin XR, Metadate CD, Methylin, Methylin, Ritalin, Ritalin SR, Ritalin LA, and Strattera, which are manufactured by a host of drug companies including Eli Lilly and Co, Novartis AG, Johnson & Johnson, and Shire plc.
Read More….


Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: